RxDoctor Payments Data

Haley Ellis, MD

Medical Oncology · Boston, MANPI 1972098820

Payments from drug & device makers

$436,356in general payments, 2019–2025

Across 29 payments — averaging $15,047 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$290K
  • Incyte Corporation$126K
  • Jazz Pharmaceuticals Inc.$18K
  • AstraZeneca$2K
  • Dilon Technologies, Inc.$149
  • Revance Therapeutics, Inc.$14

What the payments were for

  • Consulting fees$20,59697%
  • Food & beverage$7303%

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$436,356 in reported general payments places this provider in the 65th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$23,100
Medicare patients
57
Services billed
230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →